I 
116TH CONGRESS 
1ST SESSION H. R. 4814 
To improve reporting of the distribution of controlled substances, and for 
other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
OCTOBER 23, 2019 
Ms. MATSUI (for herself and Mr. JOHNSON of Ohio) introduced the following 
bill; which was referred to the Committee on Energy and Commerce, and 
in addition to the Committee on the Judiciary, for a period to be subse-
quently determined by the Speaker, in each case for consideration of such 
provisions as fall within the jurisdiction of the committee concerned 
A BILL 
To improve reporting of the distribution of controlled 
substances, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Suspicious Order Iden-
tification Act of 2019’’. 
SEC. 2. STRENGTHENING ARCOS. 
Section 307(d) of the Controlled Substances Act (21 
U.S.C. 827(d)) is amended to read as follows: 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(1)(A) Every registrant under section 303 shall and 
in such form as the Attorney General may require, make 
reports in electronic format to the Attorney General of 
every sale, delivery, or other disposal (other than by dis-
pensing by a practitioner) by the registrant of any con-
trolled substance, identifying by the registration number 
assigned under this title the person or establishment (un-
less exempt from registration under section 302(d)) to 
whom such sale, delivery, or other disposal was made. 
‘‘(B) Every registrant shall make each report re-
quired under subparagraph (A)— 
‘‘(i) not later than 30 days after the sale, deliv-
ery, or other disposal; or 
‘‘(ii) after the date on which the real-time re-
porting system is established under section 3(e)(3) 
of the Suspicious Order Identification Act of 2019 
is implemented, in real time.’’. 
SEC. 3. SUSPICIOUS ORDERS TASK FORCE. 
(a) DEFINITIONS.—In this section: 
(1) ADMINISTRATOR.—The term ‘‘Adminis-
trator’’ means the Administrator of the Drug En-
forcement Administration. 
(2) CONTROLLED
SUBSTANCE; DISTRIBUTOR; 
MANUFACTURER.—The 
terms 
‘‘controlled 
sub-
stance’’, ‘‘distributor’’, and ‘‘manufacturer’’ have the 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
meanings given those terms in section 102 of the 
Controlled Substances Act (21 U.S.C. 802). 
(3) REAL TIME.—The term ‘‘real time’’ means 
with as little delay as technically and economically 
feasible, as determined by the Attorney General fol-
lowing the program designed under subsection 
(e)(1), but not to exceed 24 hours. 
(4) REGISTRANT.—The term ‘‘registrant’’— 
(A) means a person registered under sec-
tion 303 of the Controlled Substances Act (21 
U.S.C. 823); and 
(B) does not include practitioner. 
(b) ESTABLISHMENT.—The Attorney General, in 
consultation with the Director of the Office of National 
Drug Control Policy and the Secretary of Health and 
Human Services, shall establish a Suspicious Order Moni-
toring Task Force (referred to in this section as the ‘‘Task 
Force’’). 
(c) COMPOSITION.— 
(1) IN
GENERAL.—The Task Force shall be 
composed of appropriate personnel from— 
(A) the Department of Justice; 
(B) the Drug Enforcement Administration; 
(C) the Office of National Drug Control 
Policy; 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
(D) the National Institute of Standards 
and Technology; and 
(E) other appropriate Federal, State, and 
local law enforcement and regulatory agencies 
with experience in investigating and prosecuting 
illegal transactions of controlled substances as 
determined by the Attorney General, in con-
sultation with the Secretary of Health and 
Human Services. 
(2) CONSULTANTS.—The Task Force shall con-
sult with— 
(A) industry members, including— 
(i) data analytic professionals; 
(ii) community pharmacies that dis-
pense controlled substances; 
(iii) chain pharmacies that dispense 
controlled substances; 
(iv) distributors of controlled sub-
stances; 
(v) manufacturers of controlled sub-
stances; 
(vi) State and local public health offi-
cials; and 
(vii) other relevant industry profes-
sionals; and 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS